Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection

Shorla Oncology (‘Shorla’), and EVERSANA®, a leading provider of commercialization services to the life science industry, today announced the commercial launch of the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens

Read more at:–eversana-announce-commercial-launch-of-recent-fda-approved-nelarabine-injection-for-the-treatment-of-t-cell-leukemia-across-the-united-states-301825409.html